Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Solaredge Technologies Inc (SEDG) Price & Performance

Adaptive Biotechnologies CorpTrade
Solaredge Technologies IncTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Solaredge Technologies Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Solaredge Technologies Inc trades at $33.31 (market cap $2.05B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.

ADPTSEDG
Market Cap
$4.04B$2.05B
Sector
HealthTechnology
52-Week High
$25.45$78.51
52-Week Low
$12.30$25.10
Enterprise Value
$4.10B$1.91B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.

Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.

Solaredge Technologies Inc

SolarEdge Technologies (SEDG) trades at $32.34, up 0.4% on the day, amid a challenging period marked by negative profitability and a bearish technical signal. Recent Q2 2026 earnings beat expectations with a surprise profit, but weak Q3 guidance and a net loss under GAAP accounting highlight ongoing struggles. The stock faces headwinds from soft U.S. residential demand and policy dependency, while European growth offers some offset. Analyst sentiment is mixed, with a consensus price target of $35.15 but a majority hold rating reflecting execution risks.

The outlook remains cautious due to persistent losses, high debt, and volatile cash flows. Investment opportunity hinges on margin recovery and policy support, but risks include competitive pressures, liquidity concerns, and macroeconomic sensitivity. Near-term performance will depend on Q3 results and U.S. market trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Solaredge Technologies Inc

SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.

Read more on SEDG